Viatris closes divestitures of OTC business
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dyslipidemia is a critical risk factor for cardiovascular diseases
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Ibara will drive AI-powered clinical research innovation
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Subscribe To Our Newsletter & Stay Updated